Residual risk of HIV transmission through blood transfusion in five blood banks in Cameroon

Elvige Geukeng Dongmo1,2, Dickson Shey Nsagha3, Denis Zofou4, Anna Longdoh Njunda5, Aubin Joseph Narfack2,3, Joseph Fokam4,5, Claude Tayou Tagnya4,6, Alexis Ndjola2

1 Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, Buea, Cameroon
2 Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon
3 Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, Buea, Cameroon
4 Department of Biochemistry, Faculty of Sciences, University of Buea, Buea, Cameroon
5 Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaounde, Cameroon
6 Haematology and Blood Transfusion Service, University Teaching Hospital, Yaoundé, Cameroon

Abstract

Background: Cameroon remains a country with high HIV prevalence among blood donors so there is a need for surveillance of HIV transmission through blood transfusion in order to evaluate blood safety and justify the change of screening strategy. The last evaluation of the HIV screening strategy in Cameroon in 2011 revealed that 55 HIV transmissions per 10,000 of blood donations could have prevented using a four generation assay than using a combination of third generation Rapid diagnostic test and Enzyme immuno-Assay.

Aims and objectives: This study aimed to estimated and compare the HIV transmission risk among blood banks using different testing strategies.

Study design and setting: A one year multi-center data records review study was conducted in five Blood Banks located in five regions of Cameroon in 2018. These Blood Banks were made of Yaounde Central Hospital (YCH), Douala Laquintinie Hospital (DLH), Bertoua Regional Hospital (BRH), Ebolowa Regional Hospital (ERH) and Maroua Regional Hospital (MRH).

Material and methods: Records were reviewed using data from the 1st January to the 31st December 2017. Five blood banks out of 18 were selected based on the use of national standardized registries and properly completed data. The World Health Organisation incidence/window period model was used to estimate the residual risk.

Statistics: The incidence (percentage and 95% confidence interval) of HIV was calculated per 100,000 blood donations in 2017. The chi-square test was used to measure the association between groups and P-values <0.05 were considered significant. The study was approved by the National Institutional Ethics Committee.

Results: Overall, 22,980 blood donor candidates were received and 20,430 (88.90%) [95% CI, 88.49-89.30] were tested for HIV. Among the 20,430 tested for HIV, 1827 [8.94%] [95% CI, 8.55-9.34] donated at least twice. HIV prevalence was estimated at 471/20,430 (2.31%) [95% CI, 2.11-2.52] among blood donors with an inconclusive rate of 701/20,430 (3.43%) [95% CI, 3.19-3.69]. Comparing HIV prevalence per Region between blood donors and the general population, the prevalence was mostly lower among blood donors than in the general population except in YCH and MRH. The rate of reactivity of the first-line test differ with the one of the second-line test with a kappa agreement of 0.556 (0.526-0.585: CI 95%) giving a moderate level of agreement between first and second-line test. Considering the HIV testing algorithm, incidence rates ranged from 411.52 to 1946.47 per 100,000 person-year corresponding to a residual risk to transmit HIV associated with the window period varied from 1 in 669.7 donations to 1 in 5543.54 donations. At the blood banks level, the incidence rates ranged from 382.41 to 2834.01 per 100,000 person-year and the residual risk to transmit HIV associated with the window period varied from 1 in 460 donations to 1 in 5965 donations.

Conclusion: The residual risk of HIV transmission remains high in Cameroon and varies according to the screening strategies. Thus, there is a need to revise the HIV testing strategy and implement an existing plan to recruit and retain voluntary and regular blood donors.

Keywords: Blood donation, HIV transmission, Residual risk, Cameroon blood banks.

INTRODUCTION

Blood transfusion is one of the known therapeutic interventions that cuts across a number of clinical disciplines providing unique and life-saving benefits to patients. Blood can save lives, but can also be a vector for harmful infectious diseases, such as HIV infection and viral hepatitis. Despite significant efforts
around the world to reduce transfusion-transmitted infections (TTIs), blood-borne HIV may still represent up to 10% of HIV infection in Sub-Saharan Africa. Bloch and collaborators in 2012 justified this issue by higher prevalence and less comprehensive testing standards [2]. The prevalence of HIV through transfusion during blood donations varies from 0.001% to 0.04% in High-income countries while it ranges from 0.56% to 2.69% in low-income countries [3].

In Cameroon, blood transfusion services are still hospital-based and practices vary from one blood bank to another. Previous studies report an HIV prevalence of 3.7% among the general population aged from 15 to 64 year old with an incidence of 0.27% [4], a high degree of viral diversity [5] and higher and varied prevalence from 1.2% to 5.13% reported among blood donors [6-8]. Meanwhile, HIV prevalence varies from one region to another, with the South region having the highest prevalence (6.3%) and the Far North the lowest (1.5%) [4]. Using the Yield method, a risk of 55 HIV transmissions per 10,000 of donations were reported by Tagny and collaborators using one Ab rapid diagnostic test (RDT) combined with one third-generation EIA (Enzyme Immuno-Assays) strategy. Authors revealed that another testing strategy using one fourth-generation EIA (Genscreen ULTRA HIV Ag/Ab) could have prevented 55 HIV transmissions per 10,000 donations and the risk with the fourth generation EIA was less than 1 in 2,000 donations [10].

To reduce the risk of HIV transmission through transfusion, the Cameroon National Blood Transfusion Program (NBTP) recommend in 2017 the use of two highly sensitive (99.5%) and specific (99.5%) fourth-generation EIA/CLIA in parallel or two 4th generation rapid diagnostic tests (RDT) in emergency situations or remote areas for HIV screening [11] while WHO recommend a highly sensitive and specific anti-HIV-1 + anti-HIV-2 immunoassay or HIV combination antigen-antibody immunoassay (EIA/CLIA) that is able to detect subtypes specific to the country or region or a highly sensitive and specific anti-HIV-1 + anti-HIV-2 rapid assay in laboratories with small throughput, in remote areas or emergency situations [12].

Cameroon remains a country with high HIV prevalence among blood donors so there is a need for surveillance of HIV transmission through blood transfusion in order to evaluate blood safety and justify the change of screening strategy.

Eight years after the estimation of the residual risk of HIV transmission in one hospital based blood bank in Cameroon, it is important to assess its evolution in a larger sample and more blood banks using different testing approaches prior to the implementation of the NBTP recommendations and the establishment of the National and Regional Blood Transfusion Centres. Thus, this study intended to estimated and compare the HIV transmission risk among blood banks using different testing strategies.

**MATERIALS AND METHODS**

This was a multi-center retrospective study, conducted in five blood banks located in five regions of Cameroon. These five Blood Banks were made of Yaounde Central Hospital (YCH), Douala Laquintinie Hospital (DLH), Bertoua Regional Hospital (BRH), Ebolowa Regional Hospital (ERH) and Maroua Regional Hospital (MRH). Two of the Blood Banks belong to the second category hospitals and three to the third category hospitals.

**Data collection**

Eighteen blood banks from the ten regions of the country were enrolled in this study among which five were retained (Figure1). The data were manually extracted from registries from the 1st January to the 31st December 2017. The five blood banks included in this study were using national standardized registries provided by National Blood Transfusion Program in each phase of the blood donation process.

At these blood banks, each phase of the transfusion chain from donor selection to blood distribution is recorded in a specific registry and as such, there were registries for: blood donor candidate, blood collection, blood preparation (Fragmentation), Transfusion Transmitted Infections (HIV, HBV, HCV, syphilis), blood grouping, hemovigilance and blood distribution. Data were extracted from blood donor candidate, blood collection, TTIs and blood distribution registries. These data extracted included: the gender, age, the type of donation (first-time donor, lapsed, regular), the type of donor (voluntary/family/paid), the interval between the two last donations, the HIV screening assays and HIV test result for the first line and second-line test.

The general practice among blood banks included in this study was to invite blood donors to come back two weeks after their donation to get their testing results (blood grouping, HIV, HBV, HCV, syphilis). Thus, before the next donation, a repeat donor testing results was verified and those previously tested positive were excluded for donation.

**Blood bank classification**

With respect to the hospital level, first category hospitals correspond to General hospitals and University teaching hospitals that are the fourth reference hospital; second category hospitals correspond to Central hospitals that are the third level of reference; third category hospitals correspond to Regional hospitals that are the second level of reference and fourth category hospitals correspond to District hospitals that are the first level of reference [13].

**Demographics of donors**

In this study, a regular or repeat blood donor was a person who has donated blood at least twice in the same blood bank in 12 months’ time; lapsed blood donor was a person who had a history of donation but the interval between two donations was more than 12 months. Every person whose blood was tested for the first time for infectious disease markers in a blood bank was considered as a first time donor [14].

**HIV screening strategies per blood bank**

Each blood bank included in this study practiced HIV pre-donation testing. Pre-donation testing approaches consist of testing the potential blood donors for TTIs before he donates blood, so potential blood donors are tested and their ability to donate depends both on blood donor selection and on their HIV testing result (Figure 1). Three screening strategies (A1, A2, and A3) were used by the five blood banks as described in Figure1. Although the first-line test did not vary during the study period, the second line test varied. No specific assay was used to confirm the positive result. However, repeatedly reactive results using the HIV national algorithm for RDT were considered positive. The result was negative if both first Ab RDT and the test performed at the laboratory level were non-reactive. A test result was inconclusive when the first test was reactive and the second test was inconclusive.

**Estimation of incidence and residual risk**

The incidence/window period model was used to estimate the residual risk (RR). According to this method, RR = vDWP (window period) multiplied by incidence; Incidence = number of repeat donors tested positive during one year divided by the total number of repeat donors in the year multiplied by 100,000 [14]. The Length of the viraemic phase of the diagnostic window period (vDWP) of 28 days was used for Ab RDT and 16 days for combo EIA/CLIA as recommended by WHO [14].

Blood donors tested reactive for HIV were retested following the Cameroon national algorithm for diagnosis and the result was considered positive when both first and second-line tests were repeatedly positive.
Data management

The data were extracted manually, entered using Excel software stored in a password secured Excel spreadsheets.

Statistical analysis

The SPSS software version 22 was used to analyze the collected data. Descriptive and analytical statistics were used to summarize the data obtained. The incidence (percentage and 95% confidence interval) of HIV was calculated per 100,000 blood donations in 2017. The chi-square test was used to measure the association between groups and a p-value <0.05 was considered significant.

Ethical clearance

This study was approved by the National Ethics Committee.

RESULTS

1. Demographics of Donors

According to the five blood banks selected for RR estimation, 22,980 blood donor candidates were received, 2,550 (11.10%) [95% CI, 10.69-11.51] were deferred before pre-donation testing and 20,430 (88.90%) [95% CI, 88.49-89.30] were tested for HIV. The total number of individuals who donated at least twice during the study period was 1,827 (8.94%) [95% CI, 8.35-9.34] for the five participating blood banks as showing in table 1.

2. HIV prevalence

The overall HIV prevalence 2.31% (n=471) [95% CI, 2.11-2.52] with 701 (3.43 %) [95% CI, 3.19-3.69] of inconclusive results (table 1). The age range [45-50], the first time donors and family donors had a higher prevalence (p-value 0.00-0.00). Prevalence among first-time donors was 2.86 times higher than regular donors.

3. Comparison of HIV prevalence per Region

Comparing HIV prevalence per Region between blood donors and the general population, the prevalence was mostly lower among blood donors than in the general population except in YCH and MRH. This prevalence was 10 times lower among blood donors in Douala and about 2.5 times lower among blood donors in Ebolowa and Bertoua than among the general population (figure2).

4. Analysis of inconclusive results

The rate of reactivity of the first-line test was 728/20430 (3.56%) [95% CI, 3.31-3.83] while the rate of positivity of the second-line test was 915/20430 (4.48%) [95% CI, 4.20-4.77] (Table3) with a kappa agreement of 0.556 (0.526-0.585: CI 95%) giving a moderate level of agreement between first and second-line test.

5. Estimation of incidence rates and residual risks

5.1 Estimation of incidence rates and residual risks according to testing strategy

The total HIV seroconversion cases was 16 varied from 1 to 8 cases according to the algorithm (table 4). The incidence rates ranged from 411.52 to 1946.47 per 100,000 person-year corresponding to a residual risk to transmit HIV associated with the window period varied from 1 in 669.7 donations to 1 in 5543.54 donations. Considering the five participant blood banks, the incidence rate of HIV positive donors was 875.75 [95% CI, 819-936] per 100,000 person-years and the RR was 499.06 [95% CI, 460-540] per one million donations that correspond to 1 in 2004 [1/2174-1/1852] donations.

5.2 Estimation of incidence rates and residual risks according to blood bank

HIV seroconversion varied from 1 to 7 cases according to blood bank (Table). The incidence rates ranged from 382.41 to 2834.01 per 100,000 person-year and the residual risk to transmit HIV associated with the window period varied from 1 in 460 donations to 1 in 5965 donations. Considering the five participant blood banks, the incidence rate of HIV positive donors was 875.75 [95% CI, 819-936] per 100,000 person-years and the RR was 499.06 [95% CI, 460-540].

DISCUSSION

This study aimed at examining the prevalence and incidence of HIV infections among blood banks with different HIV testing strategies and to estimate the residual risks of HIV transmission based on data collected in 2017.

Demographics of blood donors

As previously described in the country, regular and voluntary blood donor rate remains low with an increase in paid donor rate as shown in this study [9,15]. According to the NBTP, only 10% of blood needs are covered each year, such situations have been described in some Sub-Saharan Africa countries [16] and this is probably the consequence of lack of full implementation of the existing strategy for promoting blood donation developed by NBTP. Recognition actions to blood donors have been established nationwide using four types of blood donor cards, however, advantages linked to each card are still to be defined [17].

Strategies and algorithms used for HIV screening

Three different strategies were used for HIV screening in the selected blood banks as described in table 1. Although a specific strategy or algorithm has not been defined by WHO, concerning blood donation screening, the use of third or fourth generation EIA combined with NAT is a routine practice in most developed countries [18] while RDT remains the widely routine practice in Sub-Saharan African countries [16]. Meanwhile, these RDT have repeatedly revealed lower sensitivity and specificity [19,20,21] and some were unable to detect some HIV-1 subtypes [20,21].

HIV seroprevalence among blood donors

The overall HIV prevalence among blood donors was lower than the global average in the general population aged 15-64 (2.31% vs 3.7%, P value = 0.06) [14]. However, this remains high, when considering the prevalence of blood donors in lower-middle countries, that is 0.20% (0.05-0.44) [3], HIV prevalence varied from 0.31 to 3.38% among blood banks. This variation could be explained by the varying HIV prevalence by region observed nationwide [4] and thus HIV prevalence among blood donors varied according to the HIV prevalence in the region where the Blood Bank is located for example Maroua and Yaounde (Figure1). Secondly, the variation could be due to the strategy in use for blood donation screening, the prevalence being 10 times lower at DLH compared to the general population. The effectiveness of donor selection using a blood donor history questionnaire that constitutes the first layer to reduce Transfusion Transmitted Infections may also justify the low prevalence.

Inconclusive results

The rate of inconclusive results was high 3.43% and varied according to blood bank from 0.23% to 4.49%. There was a moderate level agreement between the first-line test and the second-line test. According to WHO, in low prevalence settings (<5%), individuals with reactive first-line test, then non-reactive second-line test results should be considered HIV-negative with no need for specimens to be tested again on a third assay, since the negative predictive value of A2 is high (99%), and thus the probability that the negative result observed on A2 is truly negative is 99% [22]. Therefore, among the 728 blood donor
candidates who were reactive with the first-line test, the 257 non-reactive with a second-line test could have been declared negative and temporarily deferred. After applying this, the rate of inconclusive results will drop from 3.43% to 2.17%. Concerning the 2.17% non-reactive with the first-line test and reactive with the second-line test, a confirmation and differentiation assays should be performed [22,23], but such assays are not yet routine practice. Thus, blood donors with such a profile should be called for re-testing using a new sample in 14 days as is practiced now on the field. A study should be conducted to evaluated existing strategies with a focus on inconclusive results to come out with a clear and valid interpretation of results.

### HIV Incidence and Residual Risk estimation

In general, HIV prevalence was estimated to be 252.4 per 100,000 donations among first-time donors, about 3 times higher than among regular donors; this high prevalence among first-time donors has been previously reported in our country and elsewhere [24]. The overall incidence was 875.75 per 100,000 person-years corresponding to a risk of 1 in 2004 transfusions among blood banks and 1 in 2084 according to strategy. This risk is comparable with 1 in 1,366 donations reported in Burkina Faso between 2015 and 2017 [25], eight times higher than 1 in 15,462 donations reported in Gabon between 2009 to 2011 [26], more than 90 times higher than 1 in 185,000 in China [27] between 2008 to 2010 and about 1,000 time more in Italy between 2009 to 2015 (1 in 1,917,250 for HIV) [28]. The testing strategy using a combination of two Ab RDT has a high risk, 1 in 670 donations. Several factors may explain the high risk observed in this study, including the high prevalence of HIV among blood donors 3.1% and screening strategies.

### Table 1: Blood donor’s socio-demographic characteristics per blood bank in 2017

| Blood banks | YCH n (%) | DLH n (%) | ERH n (%) | BRH n (%) | MRH n (%) | Total |
|-------------|-----------|-----------|-----------|-----------|-----------|-------|
| Blood donation candidate | 13919 (51.87) | 13290 (49.12) | 13919 (51.87) | 13919 (51.87) | 13919 (51.87) | 13919 (51.87) |
| Mean age (+/- SD) | 31.1± 8.0 | 30.3± 7.8 | 31.5± 9.4 | 27.1±7.6 | 31.5± 9.4 | 30.5 ± 8.2 |
| Blood donors Tested for HIV | 10630 (89.18) | 9611 (80.51) | 10630 (89.18) | 10630 (89.18) | 10630 (89.18) | 10630 (89.18) |
| Blood donors deferred | 1289 (10.82) | 1211 (10.49) | 1289 (10.82) | 1289 (10.82) | 1289 (10.82) | 1289 (10.82) |
| Regular donors | 1046 (9.84) | 952 (10.08) | 1046 (9.84) | 1046 (9.84) | 1046 (9.84) | 1046 (9.84) |
| Lapsed donors | 2239 (21.06) | 2072 (22.16) | 2239 (21.06) | 2239 (21.06) | 2239 (21.06) | 2239 (21.06) |
| First time donors | 7345 (69.10) | 6489 (74.02) | 7345 (69.10) | 7345 (69.10) | 7345 (69.10) | 7345 (69.10) |
| Family donors | 10219 (96.13) | 9436 (98.25) | 10219 (96.13) | 10219 (96.13) | 10219 (96.13) | 10219 (96.13) |
| Voluntary donors | 347 (3.26) | 51 (0.53) | 347 (3.26) | 347 (3.26) | 347 (3.26) | 347 (3.26) |
| Paid donors | 64 (0.60) | 58 (0.60) | 64 (0.60) | 64 (0.60) | 64 (0.60) | 64 (0.60) |

### Legend: Yaounde Central Hospital (YCH), Douala Laquintinie Hospital (DLH), Bertoua Regional Hospital (BRH), Ebolowa Regional Hospital (ERH) and Maroua Regional Hospital (MRH).

### Table 2: Donor screening test result for HIV per blood bank in 2017

| Variables | N0 (%) | Seropositive n (%) [95% CI] | Inconclusive n (%) [95% CI] | χ² | p-value |
|-----------|--------|-----------------------------|-----------------------------|----|---------|
| Gender | Female | 2836 (13.88) | 75 (2.64) [0.39-3.30] | 80 (2.82) [2.24-3.50] | 5.24 | 0.07 |
| | Male | 17594 (86.12) | 396 (2.25) [0.40-2.48] | 621 (3.53) [3.26-3.81] | 20430 | |
| | Total | 20430 | 471 (2.31) [2.11-2.52] | 701 (3.43) [3.19-3.69] | |
| Age (years) | [16-20] | 707 (3.46) | 10 (0.41) [0.69-2.59] | 24 (3.39) [2.19-5.01] | 24.76 | 0.03 |
| | [20-25] | 4624 (22.63) | 87 (1.88) [0.15-3.23] | 171 (3.70) [3.17-4.28] | 5502 | |
| | [25-30] | 5458 (26.72) | 132 (2.42) [0.20-3.86] | 172 (3.15) [2.70-4.65] | 20430 | |
| | [30-35] | 4136 (20.25) | 88 (2.13) [0.71-2.61] | 150 (3.63) [3.08-4.24] | |
| | [35-40] | 2576 (12.61) | 68 (2.64) [2.06-3.33] | 88 (3.42) [2.75-4.19] | |
| | [40-45] | 1565 (7.66) | 45 (2.88) [2.10-3.83] | 49 (3.13) [2.32-4.12] | |
| | [45-50] | 808 (3.95) | 32 (3.96) [2.72-5.54] | 29 (3.59) [2.42-5.11] | |
| | [50-68] | 556 (2.72) | 9 (1.62) [0.74-3.05] | 18 (3.24) [1.93-5.07] | |
| | Total | 20430 | 471 (2.31) [2.11-2.52] | 701 (3.43) [3.19-3.69] | |
| Donation type | First time | 14143 (69.23) | 357 (2.52) [2.27-2.79] | 464 (3.28) [2.99-3.59] | 65.25 | 0.00 |
| Lapsed   | 4460 (21.83) | 98 (2.20) | [1.79-2.67] | 142 (3.18) | [2.69-3.74] |
|----------|-------------|-----------|-------------|------------|-------------|
| Regular  | 1827 (8.94) | 16 (0.88) | [0.50-1.14] | 95 (5.20)  | [4.23-6.32] |
| Total    | 20430       | 471 (2.31)| [2.11-2.52] | 701 (3.43) | [3.19-3.69] |

**Motivation**

| Family   | 18569 (90.89)| 440 (2.37)| [2.16-2.60] | 636 (3.43)| [3.17-3.70] |
|----------|--------------|----------|-------------|----------|-------------|
| Voluntary| 735 (3.60)   | 9 (1.22) | [0.56-2.31] | 14 (1.90) | [1.04-3.17] |
| Paid     | 1126 (5.51)  | 22 (1.95)| [1.23-2.94] | 51 (4.53)| [3.39-5.91] |

**Table 3**: Agreement between first-line and second-line test

| Second-line test | Total |
|------------------|-------|
| Reactive         | 471   | 257   | 728   |
| Non-reactive     | 444   | 19258 | 19702 |
| Total            | 915   | 19515 | 20430 |

**Table 4**: HIV seroconversion incidence rates and residual risk per testing strategy

| Testing strategy | N0 (%)  | Number of sero-Conversion | Incidence rate per 100,000 person-year [95% CI] | Length of window period in days (year) | An estimate of residual risk Per 1 000 000 of donation [95% CI] | Per number of donation [95% CI] |
|------------------|---------|---------------------------|-----------------------------------------------|----------------------------------------|--------------------------------------------------------|---------------------------------|
|                  |         |                           |                                               |                                        |                                                        |                                 |
| A1               | 411 (22.50)| 8 (1.94)                  | 1946.47 [1,861-2,034]                          | 28 (0.077)                             | 1493.18 [1420-1570]                                    | 669.7 [1/704-1/637]              |
| A2               | 1173 (64.20)| 7 (0.59)                  | 596.76 [550-647]                              | 16 (0.044)                             | 261.59 [230-300]                                       | 382.7 [1/4348-1/3333]            |
| A3               | 243 (13.30)| 1 (0.41)                   | 411.52 [372-453]                              | 16 (0.044)                             | 180.39 [150-210]                                       | 1 in 5543.54 [1/6667-1/4762]    |
| Total            | 1827     | 16 (0.87)                  | 875.75 [819-936]                              | 20 (0.055)                             | 479.86 [440-520]                                       | 2083.9 [1/2273-1/1923]           |

**Table 5**: HIV seroconversion incidence rates and residual risk per blood bank

| Testing strategy | N0 (%)  | Number of sero-conversions n (%) | Incidence rate per 100,000 person-year [95% CI] | Length of window period in days (year) | An estimate of residual risk Per 1 000 000 of donation [95% CI] | Per number of donation [95% CI] |
|------------------|---------|----------------------------------|-----------------------------------------------|----------------------------------------|--------------------------------------------------------|                                 |
|                  |         |                                  |                                               |                                        |                                                        |                                 |
| YCH              | 1046 (9.84)| 4 (0.38)                       | 382.41 [345-422]                              | 16 (0.044)                             | 167.63 [144-195]                                       | 1 in 5965.52 [1/6944-1/5128]    |
| DLH              | 243 (6.24)| 1 (0.41)                        | 411.52 [372-453]                              | 16 (0.044)                             | 180.39 [150-210]                                       | 1 in 5543.54 [1/6667-1/4762]    |
| ERH              | 127 (17.21)| 3 (2.36)                       | 2362.21 [2,269-2,458]                         | 16 (0.044)                             | 1035.49 [970-1100]                                     | 1 in 965.73 [1/1031-1/909]      |
| BRH              | 247 (9.65)| 7 (2.83)                        | 2834.01 [2,732-2,939]                         | 28 (0.077)                             | 2174.03 [2080-2270]                                    | 1 in 459.98 [1/481-1/440]       |
| MRH              | 164 (6.30)| 1 (0.61)                        | 609.76 [563-660]                              | 28 (0.077)                             | 467.76 [430-510]                                       | 1 in 2137.85 [1/2325-1/1961]    |
| Total            | 1827     | 16 (0.87)                       | 875.75 [819-936]                              | 20.8 (0.057)                           | 499.06 [460-540]                                       | 1 in 2003.77 [1/2174-1/1852]    |
Notes: 1-Alere Determine HIV1/2 (Alere Medical Co.Ltd.); 2- Diagnostic kit for HIV (1+2) antibody, Shanghai Kehua Bio-engineering Co., Ltd; Abbott Laboratories (KHB) or Oraquick HIV1/2 (OraSure Technologies Bethlehem, PA) 3- Rapid Test- Cassette CTK Biotech simplifying diagnostics or Shanghai Kehua Bio-engineering Co., Ltd; Abbott Laboratories (KHB) or Oraquick HIV1/2 (OraSure Technologies Bethlehem, PA) 4-Fortress HIV Ag/Ab (Fortress diagnostics limited Antrim, UK) or Murex HIV Ag/Ab (DiaSorin S.p.A UK Branch) or Architect HIV combo (Abbott Laboratories); 5- Before announcing the positive result, on the same day, repeat both tests following the same algorithm on the same sample with a different technician; 6- the blood bag is discarded. A1 strategy in use in 2017 at MRH and BRH; A2 strategy in use in 2017 at ERH and YCH, A3 strategy in use in 2017 at DLH. 1and 2 constitute the HIV national algorithm with RDT.
CONCLUSION

The residual risk of HIV transmission remains high in Cameroon and varies according to the screening strategies. Adoption of WHO guidelines for testing in low setting prevalence may significantly reduce the rate of inconclusive results. There is a need to revise the HIV testing strategy and implement an existing plan to recruit and retain voluntary and regular blood donors.

Disclosure of Conflicts of Interest: The authors declared no conflict of interest.

Authorship contributions

Conceived the study: GDE; ZD; DSN; NAL; NAJ; FJ;

Drafted the manuscript: GDE; ZD; DSN; NAL; FJ; NAJ, AN; TTCB;

Approved the final version of the submitted manuscript: All.

Acknowledgments

This study was support by the Chantal BIYA International Reference Centre for Research on HIV/AIDS prevention and management (CIRCB). We are grateful to all the colleagues at the study blood banks, to the Yaounde University Teaching Hospital staff and to the National Blood Transfusion Program of Cameroon, for their contributions to the achievements of this study.

REFERENCES

1. Roberts DJ, Field S, Delaney M, Bates I. Problems and Approaches for Blood Transfusion in the Developing Countries. Hematol. Oncol. Clin. North Am.2016; 30(2).
2. Bloch EM, Vermeulen M, Murphy E. Blood Transfusion Safety in Africa: A Literature Review of Infectious Disease and Organizational Challenges. Transfus Med Rev [Internet] 2012;26(2):164–80. Available from: http://dx.doi.org/10.1016/j.tmrv.2011.07.006
3. World Health Organization. 2016 Global Status Report on Blood Safety and Availability [Internet]. 2017. Available from: http://apps.who.int/bookorders.
4. MoPH. CAMEROON POPULATION-BASED HIV IMPACT ASSESSMENT CAMPBIA 2017. 2018.
5. Rodgers MA, Vallari AS, Harris B, Yamaguchi J, Holzmayer V, Forberg K et al. Identification of rare HIV-1 Group N, HBV AE, and HTLV-3 strains in rural South Cameroon. Virology 2017; 504(January):141–51.
6. Tagny CT, Ndoumba A, Laperche S, Murphy E, Mbanya D. Reducing risks of Transfusion-transmitted infections in a resource-limited hospital-based blood bank: the case of the Yaoundé University Teaching Hospital, Cameroon. ISBT Sci Ser 2016; 11(2):82-7.
7. Firmin Ankouane, D Noah Noah, Atangana MM, Kamgain Simo RG, Sida MB. Séroprévalence des virus des hépatites B et C, du VIH-1/2 et de la syphilis chez les donneurs de sang de l’hôpital central de Yaoundé, région du centre, Cameroun. Transfus Clin Biol 2015;6–11.
8. Eboumbou Moukoko CE, Ngo Sack F, Essangui Same EG, Mbangue M, Lehman LG. HIV, HBV, HCV and T. pallidum infections among blood donors and transfusion-related complications among recipients at the Laquintinie hospital in Douala, Cameroon. BMC Hematol 2014; 14(1):5.
9. Marcellin Guiaro Ndoe, Octavie Danielle Moankong Fak, Arnel Herve Nwabo Kamdie, Charles Fokunang Ngungwe AMNN. Seroprevalence of Infectious Makers on Blood Donors at the Blood Bank of Bertoua Regional Hospital (Cameroon). Sci J Public Heal 2014; 51(January):184–90.
10. Tagny CT, Mbanya D, Leballais L, Murphy E. Reduction of the risk of transfusion-transmitted human immunodeficiency virus (HIV) infection by using an HIV antigen/antibody combination assay in blood donation screening in Cameroon. Transfusion 2011; 51(January):184–90.
11. MoPH. National algorithm for Transfusion Transmitted Infections. 2017.
12. WHO. Screening Donated Blood for Transfusion-Transmissible Infections [Internet]. World Heal. Organ. Web Site2010;72. Available from: http://www.who.int/bloodsafety/ScreeningDonatedBloodforTransfusion.pdf. ISBN 978 92 4 154788 8
13. MoPH. National Health Development Plan 2016-2020. 2015.
14. World Health Organisation (WHO). WHO GUIDELINE ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA. 2016.
15. MoPH. Rapport d’activités 2016 du Programme National de Transfusion Sanguine du Cameroun, 2017.
16. Weimer A, Tagny CT, Tapko JB, Gouws C, Ness PM, Bloch EM. Blood transfusion safety in sub-Saharan Africa: a literature review

**Figure 3.** Comparison of HIV prevalence per region between blood donors and general population from the 1st January to the 31st December 2017 [4]
of changes and challenges in the 21st century. Transfusion 2019; 59(January):412–27.

17. Ministry of public health (Cameroon). Guideline on the relationship between the National Blood Transfusion Program and Associations Using for the Promotion of Blood Donation. 2017.

18. Garraud O, Filho LA, Tayou-tagny C, Pozzetto B. The infectious risks in blood transfusion as of today – A no black and white situation. Presse Med [Internet] 2019;45(7, 8):e303–11. Available from: http://dx.doi.org/10.1016/j.pmed.2016.06.022

19. Kosack CS, Shanks L, Beelaert G, Benson T, Savane A, Ng A, et al. HIV misdiagnosis in sub-Saharan Africa: performance of diagnostic algorithms at six testing sites. J Int AIDS Soc 2017; 20:1–18.

20. Aghokeng AF, Mpoudi-ngole E, Dimodi H, Atem-tambe A, Tonglo M. Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon. PLoS One 2009; 4(11):1–6.

21. Njouom R, Ngono L, Mekinda-Gometi DD, Ndé CK, Sadeuh-Mba SA, Vernet M-A, et al. Evaluation of the performances of twelve rapid diagnostic tests for diagnosis of HIV infection in Yaounde, Cameroon. J Virol Methods [Internet] 2017;243:158–63. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L614522061%0Ahttp://dx.doi.org/10.1016/j.jviromet.2017.02.008

22. World Health Organization (WHO). HIV Testing Services: WHO Consolidated Guidelines. 2015.

23. APHL. Suggested Reporting Language for the Diagnostic Testing Algorithm. 2019.

24. Yang S, Jiao D, Liu C, Lv M, Li S, Chen Z, et al. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses, and Treponema pallidum infections among blood donors at Shiyan, Central China. BMC Infect Dis 2016;16(1).

25. Yooda AP, Sawadogo S, Soubeiga T, Obiri-yebobra D, Nebie K, Ouattara AK, et al. Residual risk of HIV, HCV, and HBV transmission by blood transfusion between 2015 and 2017 at the Regional Blood Transfusion Center of Ouagadougou, Burkina Faso. J Blood Med 2017; 10:53-8.

26. Rerambiah LK, Rerambiah LE, Bengone C, Siawaya JFD. The risk of transfusion-transmitted viral infections at the Gabonese National Blood Transfusion Centre. Blood Transfus 2014; 12(3):330-3.

27. Song Y, Bian Y, Petzold M, Ung COL. Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One2014; 9(4).

28. Velati C, Romanò L, Pati I, Marano G, Piccinini V, Catalano L et al. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018. Blood Transfus. 2018; 17:409–17.